Buserelin Acetate
It is a synthetic peptide analog of the natural gonadotropin releasing hormone (GmRH/LHRH) with enhanced biological activity. After repeated administration of buserelin, the secretion of gonadotrophin release and gonadal steroids is significantly inhibited. The pharmacological effect is attributable to the down-regulation of pituitary LHRH receptors.Subcutaneous injection, The palliative Treatment (initial and maintenance treatment) of patients with hormone-dependent advanced carcinoma of the prostate gland (stage D). Nasal solution; The palliative Treatment (maintenance treatment) of patients with hormone-dependent advanced carcinoma of the prostate gland (stage D). The treatment of endometriosis in patients who do not require surgery as primary therapy. The duration of Treatment is usually six months and should not exceed nine months.
Patients with Prostatic Cancer Initial treatment: For the first seven days of treatment give buserelin 500mcg (0.5ml) every 8 hours by subcutaneous injection. For patient comfort, vary the injection site. Maintenance treatment: Depending upon patient preference, or Physician recommendation, maintenance treatment may be by daily subcutaneous injection or by intranasal administration three times daily. During maintenance dosing by the subcutaneous injection route, the buserelin dose is 200mc
Hypersensitivity, Prostate cancer who do not present with hormone dependent carcinoma and in patients who have undergone orchiectomy, undiagnosed vaginal bleeding.
Paediatrics: data not sufficient. Pregnancy: contraindicated Lactation: contraindicated Elderly: data not sufficient
Hot flushes, loss of libido, impotence, nasal irritation (nasal solution) and headache (nasal solution)
Antiarrythmic drugs, opoids, macrolide antibiotics
Brand Name | Manufactured by |
---|---|
BUSARDIN | INTAS PHARMACEUTICALS LTD. |